Orphazyme CEO on trading explosion: "We have no idea what is going on"
The Danish company has not made any announcements over the past 24 hours, so CEO Christophe Bourdon is very surprised at the 300 percent value jump its shares made in the US on Thursday, which rubbed off on the Danish listing on Friday.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
Thursday was a noteworthy day for Orphazyme in every sense of the word.
When trading closed on the Nasdaq exchange in Copenhagen on Thursday, the share price had dropped by 0.2 percent, giving the company a share value of DKK 31.1.
The FDA rejection of Orphazyme's drug candidate in its main indication will trigger major cuts at the biotech firm, but CEO Christophe Bourdon has no comment on where they will be implemented and how hard the US organization will be hit.